Mary Kay Fenton Sells 4,398 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) CFO Mary Kay Fenton sold 4,398 shares of the business’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $13.62, for a total transaction of $59,900.76. Following the transaction, the chief financial officer directly owned 126,380 shares of the company’s stock, valued at approximately $1,721,295.60. This represents a 3.36% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Cullinan Therapeutics Price Performance

NASDAQ CGEM opened at $14.27 on Wednesday. The company’s 50 day simple moving average is $11.41 and its two-hundred day simple moving average is $9.27. Cullinan Therapeutics, Inc. has a 1 year low of $5.68 and a 1 year high of $14.56. The stock has a market capitalization of $843.01 million, a PE ratio of -4.31 and a beta of -0.09.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on CGEM shares. Wall Street Zen cut Cullinan Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, February 8th. Zacks Research downgraded Cullinan Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 19th. BTIG Research upped their price objective on shares of Cullinan Therapeutics from $32.00 to $38.00 and gave the stock a “buy” rating in a research report on Monday, November 24th. New Street Research set a $26.00 target price on shares of Cullinan Therapeutics in a research note on Thursday, November 20th. Finally, Guggenheim started coverage on shares of Cullinan Therapeutics in a research note on Monday, February 2nd. They issued a “buy” rating and a $30.00 price target for the company. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Cullinan Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $29.33.

Key Stories Impacting Cullinan Therapeutics

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: Bullish independent thesis — A Seeking Alpha write‑up upgrades Cullinan to a Buy, highlighting a deep T‑cell engager pipeline (notably CLN‑049 showing ~30% CR in AML), a strong cash runway (~$430M+), and a clear regulatory path that supports upside expectations. Seeking Alpha: Thesis Strengthening For This T-Cell Engager Specialist
• Positive Sentiment: Investor conference participation — Management (CEO Nadim Ahmed and CMO Jeffrey Jones) announced attendance at upcoming investor conferences, which increases investor access to clinical updates and can support multiple‑stakeholder visibility. GlobeNewswire: Cullinan Therapeutics to Participate in Upcoming Investor Conferences
• Positive Sentiment: Analyst momentum — Multiple firms have issued Buy/Outperform ratings and lifted price targets in recent months (consensus/average target materially above current levels), which can attract momentum buyers. MarketBeat: CGEM analyst coverage
• Neutral Sentiment: Technical/fundamental backdrop — The stock is trading above the 50‑ and 200‑day moving averages and is well above its 52‑week low, reflecting short‑term strength; market cap and high institutional ownership (~86%) mean moves can be amplified by flows. MarketBeat: CGEM profile
• Negative Sentiment: Clustered insider sales — Several insiders (CEO Nadim Ahmed, CFO Mary Kay Fenton and others) sold shares around Feb 20 (combined ~20k+ shares across multiple filings). While the percentages trimmed are modest (low single digits), simultaneous sales by senior executives can create near‑term selling pressure and raise questions for some traders. InsiderTrades: CGEM insider transactions

Institutional Investors Weigh In On Cullinan Therapeutics

A number of hedge funds have recently made changes to their positions in CGEM. Invesco Ltd. grew its holdings in shares of Cullinan Therapeutics by 27.4% during the 4th quarter. Invesco Ltd. now owns 130,323 shares of the company’s stock valued at $1,349,000 after purchasing an additional 28,011 shares during the last quarter. Virtus Investment Advisers LLC lifted its stake in Cullinan Therapeutics by 75.5% in the fourth quarter. Virtus Investment Advisers LLC now owns 22,318 shares of the company’s stock worth $231,000 after purchasing an additional 9,604 shares during the last quarter. Susquehanna Portfolio Strategies LLC boosted its position in Cullinan Therapeutics by 87.8% during the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 233,842 shares of the company’s stock valued at $2,420,000 after buying an additional 109,311 shares during the period. Elmind Capital LP bought a new position in shares of Cullinan Therapeutics during the fourth quarter valued at about $3,208,000. Finally, Engineers Gate Manager LP increased its holdings in shares of Cullinan Therapeutics by 37.7% in the fourth quarter. Engineers Gate Manager LP now owns 69,343 shares of the company’s stock worth $718,000 after buying an additional 18,980 shares during the period. 86.31% of the stock is currently owned by institutional investors.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.